Growth Metrics

Lipocine (LPCN) Change in Accured Expenses (2016 - 2025)

Lipocine's Change in Accured Expenses history spans 13 years, with the latest figure at $63888.0 for Q3 2025.

  • For Q3 2025, Change in Accured Expenses rose 8.64% year-over-year to $63888.0; the TTM value through Sep 2025 reached -$542618.0, down 457.05%, while the annual FY2024 figure was -$297246.0, 311.19% down from the prior year.
  • Change in Accured Expenses reached $63888.0 in Q3 2025 per LPCN's latest filing, down from $66369.0 in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $472012.0 in Q2 2024 to a low of -$554554.0 in Q4 2021.
  • Average Change in Accured Expenses over 5 years is -$47553.2, with a median of $55888.0 recorded in 2023.
  • Peak YoY movement for Change in Accured Expenses: surged 645.79% in 2022, then plummeted 917.74% in 2024.
  • A 5-year view of Change in Accured Expenses shows it stood at -$554554.0 in 2021, then surged by 135.5% to $196888.0 in 2022, then plummeted by 60.3% to $78173.0 in 2023, then crashed by 574.65% to -$371045.0 in 2024, then surged by 117.22% to $63888.0 in 2025.
  • Per Business Quant, the three most recent readings for LPCN's Change in Accured Expenses are $63888.0 (Q3 2025), $66369.0 (Q2 2025), and -$301830.0 (Q1 2025).